GangaGen have established an efficient platform for novel anti-bacterial drug development. The approach leverages a deep understanding of the biology of bacteriophages (nature’s anti-bacterial), combined with cutting-edge biotechnology to develop innovative solutions for the important health care problem caused by antibiotic-resistant organisms.
This platform is being used to develop a completely new class of antibacterial agents, called ectolysins. These are different from currently available antibiotics in key ways. Each ectolysin is specific to the type of bacteria for which it is developed, and can rapidly destroy the bacteria, including those in biofilms, leaving beneficial bacteria unaffected.
This approach offers the potential of a powerful new paradigm to effectively treat drug resistant bacterial infections.